Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2021-12-14 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司公司章程
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association for 江苏四环生物股份有限公司 (Jiangsu Sihuan Bioengineering Co., Ltd.). It includes comprehensive sections on company organization, shareholder rights, board structure, share issuance, shareholder meetings, voting procedures, and other governance matters. The content is focused on internal governance rules, shareholder meeting procedures, board and management roles, and company operational scope. There is no indication of financial statements, audit reports, earnings data, or announcements of voting results. The document is not a report of financial performance or a meeting presentation but rather a governance document outlining the company's internal rules and structure. Therefore, the most appropriate classification is Governance Information (CGR).
2021-12-14 Chinese
江苏四环生物股份有限公司第九届董事会第九次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at the ninth meeting of the ninth board of directors of Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, voting results, and decisions such as amendments to the company charter, appointment of a non-independent director candidate, and approval of the independent director work system. It also mentions that these resolutions require shareholder approval. The document does not contain financial statements or detailed financial analysis but focuses on board decisions and management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short (1294 characters), and it is not an announcement of a report publication but a substantive announcement of board resolutions.
2021-12-14 Chinese
2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '江苏四环生物股份有限公司 2021 年第三季度报告' which translates to 'Jiangsu Sihuan Biological Co., Ltd. 2021 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the third quarter of 2021. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. There is no indication that this is an announcement of a report or a certification document. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2021
2021-10-28 Chinese
江苏四环生物股份有限公司2021年前三季度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a '2021 年前三季度业绩预告' which translates to '2021 First Three Quarters Earnings Forecast'. It provides estimated financial performance for the period January 1 to September 30, 2021, including net profit and earnings per share, but explicitly states that the forecast is unaudited and preliminary. It also mentions that the final data will be in the 2021 third quarter report. The document is short (943 characters) and serves as an earnings forecast announcement rather than a full financial report. This fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. 9M 2021
2021-10-14 Chinese
江苏四环生物股份有限公司关于实际控制人部分股份解除质押及再质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the partial release and re-pledging of shares by the actual controller of the company, including detailed information about share pledges, shareholders involved, and risk disclosures. It does not contain financial statements, audit results, or detailed financial performance data. It is a regulatory announcement about share pledging activities, which fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters, but it contains substantive information about financing activities (share pledges), not just a report publication notice. Therefore, the appropriate classification is CAP with high confidence.
2021-09-15 Chinese
2021年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "江苏四环生物股份有限公司 2021 年半年度报告全文" which translates to "Jiangsu Sihuan Bio Co., Ltd. 2021 Semi-Annual Report Full Text." It contains detailed financial data, management discussion and analysis, company governance, environmental and social responsibility, important matters, litigation updates, and other comprehensive sections typical of a semi-annual financial report. The document includes actual financial statements and substantive financial data for the half-year period ending in 2021. It is not a brief announcement or a certification letter but a full report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-27 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.